“Creatine synthesis from guanidinoacetate, a reaction catalyzed by guanidinoacetate methyltransferase (GAMT), consumes ∼50% of S-adenosylmethionine (SAM)-derived methyl groups, accounting for an equivalent proportion of S-adenosylhomocysteine (SAH) and total homocysteine (tHcys) synthesis.” “Dietary creatine intake inhibits synthesis of guanidinoacetate in the rat kidney by pretranslational inhibition of arginine:glycine amidinotransferase (AGAT) … Studies in rats have demonstrated that plasma tHcys concentrations can be lowered by creatine supplementation in the diet, which reduces methylation demand.” “Our findings indicate that whereas creatine supplementation downregulates endogenous creatine synthesis, this may not on average lower plasma tHcys in humans.”

“The GAA is then methylated by the enzyme guanidinoacetate N‑methyltransferase (GAMT) with **S‑adenosyl methionine (SAMe) to form creatine**… Creatine synthesis accounts for **up to 40% of the labile methyl groups** derived from SAMe, and therefore plays a major role in methylation balance.” This review describes that reducing endogenous creatine synthesis (for example by providing creatine exogenously) would be expected to **spare SAMe for other methylation reactions** because less SAMe is consumed in the GAA→creatine step.

Creatine is synthesized endogenously from L-arginine, glycine, and L-methionine via a two-step reaction catalyzed by AGAT and GAMT. The generation of creatine in this pathway requires methylation of guanidinoacetate (GAA) by S-adenosylmethionine (SAM) as the methyl donor. Thus, creatine synthesis is estimated to consume a substantial proportion (up to 40–70%) of the labile methyl groups generated from SAM in humans. By providing preformed creatine through supplementation, the demand for endogenous creatine synthesis is reduced, which in turn may decrease the methylation burden on SAM-dependent pathways.

The title of this brief report states: "Lowering methylation demand by creatine supplementation paradoxically decreases DNA methylation." The study examines the effect of reducing the methylation demand imposed by creatine synthesis on global DNA methylation. Although the abstract text is not fully shown in the PubMed record, the key point is that creatine supplementation was used specifically to lower methylation demand (i.e., SAM-dependent methylation load), and the authors observed a paradoxical decrease in DNA methylation.

This animal study notes that “supplemental Cr has the potential to **spare methyl groups via negative feedback on AGAT activity**, lowering GAA production and the demand for methyl groups used in Cr synthesis, as well as **lowering homocysteine production**, which has been demonstrated in Cr supplemented rats.” It contrasts this with GAA: “Supplementation with GAA resulted in a ~50% lower hepatic **SAM concentration** compared to both control and Cr supplemented groups while there were no differences in hepatic SAH or SAM/SAH ratio among groups.” The authors infer that high methyl use for creatine synthesis (with GAA) limits methyl availability for other transmethylation reactions, whereas creatine itself does not lower hepatic SAM in this model.

Because the biosynthesis of creatine consumes S-adenosylmethionine (SAM), we hypothesized that creatine supplementation would down-regulate endogenous creatine synthesis and thereby spare SAM, resulting in lower plasma homocysteine concentrations. In a randomized, double-blind, crossover study, participants received creatine 20 g/d or placebo for 5 days. Creatine supplementation significantly decreased plasma homocysteine concentrations compared with placebo. The authors concluded that exogenous creatine decreases the need for methylation of guanidinoacetate to creatine, thereby sparing SAM and lowering homocysteine.

The paper notes that “creatine supplementation has been shown to down-regulate the synthesis of l-arginine : glycine amidinotransferase and consequently reduce endogenous formation of creatine, changing the methylation flux and reducing Hcy synthesis.” “As consequence, the pathway of S-adenosylmethionine (SAM) to S-adenosylhomocysteine (SAH) is down-regulated and there is a decrease in homocysteine formation.” “In conclusion, creatine supplementation by the two protocols studied reduced plasma Hcy concentrations, possibly by modulating the methyl balance.”

In this human metabolic study (Stead et al. 2005), the authors state: “**Creatine synthesis utilizes a large portion of the methyl groups from S‑adenosylmethionine**. We hypothesized that endogenous creatine synthesis is an important determinant of plasma homocysteine.” By pharmacologically inhibiting GAMT and thus creatine synthesis, they observed “a significant **decrease in plasma homocysteine concentrations**, supporting the concept that **demand for methyl groups by creatine synthesis influences homocysteine and methylation balance**.” Although this is not a supplementation trial, it is direct evidence that the creatine synthetic pathway is a major SAM consumer in humans.

S-adenosyl methionine (SAMe), as a major methyl donor, exerts its influence on central nervous system function through cellular transmethylation pathways, including the methylation of DNA, histones, protein phosphatase 2A, and several catecholamine moieties. SAMe is a metabolic product of methionine generated by methionine-adenosyltransferase (MAT)… SAMe is then utilized as a donor of its methyl group to methylate many substrates to fulfill diverse biological functions. The dysregulation of SAMe leads to alterations in >100 methyltransferase reactions… including those involved in neurotransmitter pathways.

This review notes that “**creatine synthesis demands methyl groups from S‑adenosylmethionine** and thus contributes to homocysteine formation.” It explains that providing creatine exogenously “may **down‑regulate endogenous creatine synthesis**, thereby **reducing the methylation requirement and homocysteine production**.” However, it also stresses that “evidence in humans is **inconsistent**, with some studies showing decreased homocysteine and others no effect during creatine supplementation.” The review does not present direct human data linking creatine’s methyl‑sparing effect to increased SAMe‑dependent neurotransmitter synthesis.

Because creatine synthesis accounts for a large proportion of methyl group use, we hypothesized that creatine supplementation would decrease the need for methylation and thereby lower plasma homocysteine, a product of S-adenosylmethionine-dependent reactions. In this randomized trial, oral creatine (20 g/d) for 5 days decreased plasma homocysteine by approximately 5–10% and reduced urinary excretion of creatinine plus creatine. The authors concluded that exogenous creatine downregulates endogenous creatine synthesis, which in turn reduces the flux through S-adenosylmethionine-dependent methylation pathways.

Endogenous creatine synthesis utilizes S-adenosylmethionine (SAM) as a methyl donor, producing S-adenosylhomocysteine and subsequently homocysteine. We tested whether creatine supplementation could modulate this pathway. Creatine loading (20 g/day for 5 days) reduced plasma homocysteine concentrations and urinary methylated metabolites, consistent with a reduction in the demand for SAM-dependent methylation reactions involved in creatine biosynthesis.

S-adenosylmethionine (SAMe) is produced in the liver from L-methionine and adenosine triphosphate (ATP) and is known for its role as a methyl donor in a variety of biological processes. Some of these include DNA and RNA gene expression and neurotransmitter secretion, including dopamine, norepinephrine, and serotonin, which help elevate mood and support cognitive processes. The replenishment of depleted neurotransmitters in CNS signs, like major depressive disorder, is important; however, the beneficial effects of SAMe may also be due to its anti-inflammatory properties.

This review notes that creatine is synthesized using SAM as a methyl donor: “Endogenous creatine synthesis is a significant methylation reaction, accounting for a large portion of S-adenosylmethionine-derived methyl group usage.” The authors discuss that creatine supplementation can downregulate AGAT and thereby reduce endogenous creatine synthesis, highlighting the potential for creatine to influence methylation metabolism. However, while the paper explores links between creatine, brain energy metabolism, and mood, it does not present direct experimental evidence that creatine supplementation increases SAMe availability for neurotransmitter production.

Because creatine synthesis is a major methylation reaction utilizing S-adenosylmethionine (SAM), we hypothesized that creatine supplementation would reduce methylation demand and lower plasma homocysteine. Rats fed creatine showed significantly decreased hepatic guanidinoacetate methyltransferase activity and lower plasma homocysteine compared with controls. These data support the concept that providing creatine exogenously spares SAM by decreasing the requirement for its use in creatine biosynthesis.

Beyond its role in energy homeostasis, creatine has been proposed to facilitate neuronal firing and act as a neuromodulator in the central nervous system. Experimental evidence shows that creatine is released from neurons in an activity-dependent manner and can interact with various receptors, including NMDA, GABAA, and serotonin 1A receptors. These findings suggest that creatine itself may influence neurotransmission; however, the review does not present direct measurements of S-adenosylmethionine or methylation status in relation to creatine supplementation.

Studies of methionine loading in humans have indicated that creatine synthesis via guanidinoacetate methylation is a major pathway of transmethylation. Approximately half of total methyl group flux from S-adenosylmethionine can be attributed to creatine synthesis. When exogenous creatine is provided, urinary creatinine excretion increases and endogenous synthesis is suppressed, which is reflected in reduced methylation demand. The work implies that creatine intake modulates S-adenosylmethionine utilization, but it did not assess downstream effects on neurotransmitter methylation directly.

Creatine has multiple effects in the brain, including buffering of ATP, modulation of mitochondrial function, and potential neuromodulatory actions. The review notes that creatine biosynthesis is methylation-dependent and that dietary creatine can downregulate AGAT, potentially sparing methyl groups from S-adenosylmethionine. However, the authors emphasize that evidence for creatine-induced changes in neurotransmitter synthesis via altered methylation is indirect; observed benefits on mood and cognition are more strongly linked to energy metabolism and phosphocreatine availability.

Creatine is synthesized in a two-step process beginning with formation of guanidinoacetate and followed by its methylation to creatine via guanidinoacetate methyltransferase, which uses S-adenosylmethionine (SAM) as a methyl donor. Given that cerebral creatine levels can also be maintained by uptake from the circulation, dietary creatine may reduce the need for endogenous synthesis and thus lower the utilization of SAM in the brain. The authors discuss how alterations in creatine and methylation metabolism could influence brain energy homeostasis and neurotransmission, although direct effects of creatine on SAM availability for neurotransmitter synthesis remain to be clarified.

This genetics-oriented article explains: “Creatine is synthesized in the body in a reaction that uses S-adenosylmethionine (SAMe) as a methyl donor. This process is thought to consume around 40–50% of the body’s available methyl groups.” It also notes that supplemental creatine “can downregulate endogenous creatine synthesis, which may reduce the demand for methyl groups from SAMe. This is why creatine has been investigated as a way to influence homocysteine and methylation status.” However, the article primarily discusses genetic variants in creatine metabolism and does not provide direct evidence on neurotransmitter production.

This educational page describes that after donating a methyl group to make creatine, “SAMe turns into SAH and then… into homocysteine.” It explains that the **AGAT–GAMT pathway for creatine synthesis uses SAMe‑derived methyl groups**, and that variations in methylation‑related genes (MTRR, MTR, BHMT, PEMT) can affect this cycle. While it outlines the biochemical link between SAMe, creatine, and homocysteine, it does not present experimental data on creatine supplementation increasing SAMe availability for neurotransmitter production.

Biochemistry textbooks and reviews consistently describe the methylation of guanidinoacetate to creatine by guanidinoacetate methyltransferase as one of the largest single consumers of SAM-derived methyl groups in the body, often cited in the range of about 40–50% of total SAM-dependent methylation. This is the mechanistic basis for the hypothesis that exogenous creatine, by suppressing endogenous creatine synthesis, lowers overall methylation demand and could in principle leave more SAMe available for other methylation reactions, including neurotransmitter-related pathways; however, direct in vivo evidence for increased SAMe flux into neurotransmitter synthesis following creatine supplementation is limited.